Business Segments Seelos Therapeutics, Inc.
Stocks
SEELQ
US81577F4063
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | +9,900.00% |
|
-.--% | - |
| 12-28 | Motion for Asset Sale Approved for Seelos Therapeutics, Inc. | CI |
| 25-10-21 | GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q). | CI |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||
Pharmaceuticals | 375K | - | - | - | 2.2M | |||
Total Assets | 11.1M | 17.49M | 83.5M | 22.75M | 5.42M | |||
Interest Expense | -29K | -164K | -1.6M | -14K | -75K | |||
CAPEX | - | - | - | - | - | |||
EBT | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
D&A | - | - | - | 53K | 57K | |||
Operating Income | -29.75M | -18.76M | -61.67M | -70.92M | -40.5M | |||
Net Income | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
United States | 375K | - | - | - | 2.2M | |||
Total Assets | 11.1M | 17.49M | 83.5M | 22.75M | 5.42M | |||
Interest Expense | -29K | -164K | -1.6M | -14K | -75K | |||
D&A | - | - | - | 53K | 57K | |||
CAPEX | - | - | - | - | - | |||
Net Income | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
EBT | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
Operating Income | -29.75M | -18.76M | -61.67M | -70.92M | -40.5M |
- Stock Market
- Stocks
- SEELQ Stock
- Financials Seelos Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
